In our experience, a pharmacy that shares a building with a medical clinic is one of the most requested types of pharmacy for sale in Canada. Many buyers ask for it by name. Sellers often lead with it in their teasers. Lenders generally like the recurring prescription base. And yet the clinic is also the part of the business that buyers, lenders and brokers argue about most, because the same feature that produces the volume also produces the risk.
This article explains how a pharmacy with a medical clinic is valued in practice: how referral traffic is counted, how dependence on a single clinic or physician is measured and discounted, what the lease has to say when the pharmacy and clinic share a building or a landlord, what actually happens when a clinic moves, how banks look at it, and how holdbacks tied to volume after closing are used to bridge the gap between a confident vendor and a cautious buyer. The examples are drawn from Alberta and British Columbia, but the method is the same everywhere in Canada.
Referral traffic as a valuation factor
In our experience, proximity to prescribers is one of the strongest drivers of prescription volume. Many patients who leave a clinic with a prescription fill it at the pharmacy they see on the way out (though every patient remains free to choose), and once the profile is opened, refills, family members and services often follow. That is why a pharmacy in the same building as an active clinic often fills more prescriptions than its location and competition would otherwise support.
Buyers value that traffic in two steps. First they measure it. Prescriptions by prescriber for the last two to three years, split into prescribers who practise in the building and prescribers who do not, show how much of the volume the clinic actually produces. New patient registrations by month show whether the clinic is still feeding the file or whether the store is living on refills from patients registered years ago.
Second they decide how much of it will survive a change of ownership. Clinic derived volume that flows from location, convenience and a long lease survives well. Volume that flows from a personal relationship between the vendor pharmacist and one physician survives less well. The valuation multiple moves accordingly. There is no published dataset of Canadian pharmacy sale multiples; as an illustrative range based on our observations, established community pharmacies have often been priced at roughly 4 to 6 times normalized EBITDA, with Alberta stores often higher (around 5.5 to 7.0) because of the province’s dispensing fee and paid clinical services. A clinic that produces diversified, location based traffic tends to push a store toward the top of its provincial range. A clinic that produces concentrated, relationship based traffic tends to pull it toward the bottom, or below it. These are tendencies, not automatic premiums or discounts. Our pharmacy valuation guide covers the rest of the multiple.
Dependence: the risk buyers discount
The question every buyer asks is some version of this: what happens if one physician retires?
The answer depends on the numbers, so ask for them. Take prescriptions by prescriber and calculate three shares: the top prescriber, the top three prescribers, and all prescribers practising in the building. Then find out the age and plans of each physician in the top group. A clinic with six physicians each writing around 10 percent of the pharmacy’s scripts is a diversified referral base. A clinic with one physician writing 40 percent of scripts, who is 67, has signalled plans to retire and has not recruited a successor, is a concentration risk that a buyer will price. Head count alone does not establish diversification: several physicians can share one clinic owner whose single decision could move them all, and one of several physicians may still write most of the prescriptions. Measure the actual shares from the pharmacy’s data, and assess departure risk even where several physicians practise.
How buyers price it varies, but the logic is consistent. Some apply a lower multiple to the whole business. Some value the concentrated portion of EBITDA at a lower multiple than the rest, in the same way a long term care pharmacy with one large facility contract is valued with that contract discounted. Some leave the price alone and move the risk into the structure through a holdback or an earnout, which is covered below. In our experience, few buyers will pay the full multiple in cash at closing for volume that depends on one person’s retirement date.
Vendors sometimes resist this. The most common argument is that the patients belong to the pharmacy, not the physician, and will stay whatever happens to the clinic. That is partly true for patients who live nearby and partly untrue for patients who drove to the clinic from elsewhere. A vendor who wants to defend the multiple should show where patients live without sharing anything that could identify them: an aggregated, de identified summary, for example the share of active patients by distance band from the store or by postal prefix (the first three characters of the postal code), with small counts suppressed. If most patients live within the pharmacy’s own trade area, the summary will show it. Share it under the NDA, after the pharmacy, as the holder of the records, is satisfied the disclosure is necessary and permitted under the privacy law that applies. An NDA alone does not authorize disclosing patient information, and identifiable patient records transfer only at closing. That is evidence a buyer and a lender can use.
Lease structures when pharmacy and clinic share a building
The lease is where clinic risk is either controlled or left open, and there are four common arrangements. Medical building leases also often carry demolition or relocation rights that shorten the term a lender counts; see demolition and relocation clauses.
Separate leases, same landlord. The pharmacy and the clinic each lease from a third party landlord. The buyer should ask for the clinic’s lease term, not just the pharmacy’s. A pharmacy lease with ten years remaining beside a clinic lease with eighteen months remaining is a ten year commitment to a location whose main attraction may leave next year. The buyer should also look for an exclusivity clause preventing the landlord from leasing to a second pharmacy in the development, and for a relocation clause that would let the landlord move the pharmacy away from the clinic entrance. An exclusivity clause is a commercial protection against a competing pharmacy in the building. It does not give the pharmacy any claim on patients, who remain free to fill their prescriptions anywhere.
The pharmacy vendor owns the building. The vendor leases to the clinic and operates the pharmacy. In our experience this is more common in smaller centres, and it can give a buyer the most control over the premises, provided the building is available. A buyer can take a new long term lease from the vendor with terms that match the clinic’s, or buy the building and become the clinic’s landlord. The second option gives the buyer more say over the space, and over renewal when the clinic lease comes up, but the buyer is still bound by the existing clinic lease and cannot make physicians stay. It reduces the risk of losing the premises; it does not remove the risk of losing the physicians.
The clinic owns the building. The pharmacy is the tenant of the physicians. The relationship is stable as long as the physicians are, and unstable at the moment they sell the building or retire. Buyers look for a long lease with renewal options and a clause that survives a sale of the building.
Sublease or shared space. The pharmacy subleases from the clinic or the clinic from the pharmacy. This is the arrangement most likely to attract regulatory attention, because rent that varies with prescription volume, or space that funnels patients to the pharmacy, can amount to paying for prescriptions. Pharmacy regulators generally prohibit that, directly or indirectly, but the exact rules differ by province (in Alberta, for example, see the Alberta College of Pharmacy’s Code of Ethics on professional independence and inducements). Any arrangement of this kind should be reviewed against the rules of the regulator in the province before a buyer relies on it. Lease protections are a commercial matter; the professional rules on referrals and inducements are a separate question, and patients keep their choice of pharmacy either way. Our medical clinics page describes how we structure clinic and pharmacy relationships within those rules.
In all four cases the buyer should ask for the same thing: the pharmacy’s lease term, including options, should ideally run at least as long as the loan amortization, and the clinic’s lease term should be known and long enough to matter.
What happens if the clinic moves
It happens, and buyers should model it rather than hope.
What follows is the pattern we have generally observed; the pace varies by store and there is no published data on it. In the first months after a clinic relocates, the pharmacy usually keeps most of its refill volume. Patients have their profiles there, their compliance packaging is set up, and habit is strong. New prescriptions usually fall first, because many patients leaving the new clinic location will see a different pharmacy on the way out. Over the following months or years, refills tend to follow new prescriptions, starting with the patients who live farthest away. As an illustrative scenario, a pharmacy that drew 40 percent of its scripts from the clinic should plan for losing a meaningful share of that over time unless it replaces the clinic or the patients.
The protections are practical. A clinic lease term at least as long as the pharmacy’s. An exclusivity clause in the pharmacy’s lease. A landlord, ideally the pharmacy owner, with an interest in keeping both tenants. A clinic that is recruiting and has physicians of mixed ages. And a pharmacy that has built services revenue, compliance packaging and delivery relationships that do not depend on the clinic next door. In Alberta, where many clinical services are reimbursed by the public plan when the pharmacist is eligible, the service is documented and the per pharmacist cap ($13,000 per rolling 28 days) is respected, a store with several pharmacists who hold additional prescribing authorization tends to have a revenue base that holds up better after a clinic move than a store that only dispenses.
Buyers also ask whether the vendor has any influence over the clinic. In some cases the vendor recruited the physicians, sits on the clinic’s lease as guarantor, or owns a share of the clinic entity. Those relationships have to be disclosed and, where they are part of the value, carried over to the buyer in a form the college permits.
How banks view a clinic pharmacy
Lenders like clinic pharmacies for the same reason buyers do: a recurring prescription base that does not depend on front store retail. They dislike them for the same reason buyers do: concentration.
In practice a lender asks for the prescriber breakdown described above, the pharmacy’s lease with all options, and the clinic’s lease term. Many want the pharmacy lease, including renewals, to run at least as long as the loan amortization, which in our experience is often around ten years. Each lender sets its own conditions, and only an actual lender proposal tells you what applies to your deal. Where the top prescriber’s share is high, or the clinic lease is short, lenders commonly respond in one or more of three ways. They reduce the percentage of the purchase price they will advance, which means more equity from the buyer. They require a holdback or vendor take back in the purchase agreement so that part of the price is at risk if volume falls. Or they ask for a longer clinic lease, or a letter from the clinic confirming its intentions, as a condition of funding.
Lenders will not take the vendor’s word for the strength of the relationship. They want the numbers, the leases, and the structure. A vendor who assembles those before listing sells to a buyer whose financing holds. A vendor who does not risks losing a buyer at the credit committee stage, months into the process. Our article on how Canadian banks evaluate pharmacy financing covers the general requirements.
Holdbacks tied to volume after closing
When a vendor believes the clinic relationship is secure and a buyer is not sure, the gap is usually bridged with structure rather than argument.
A holdback is a portion of the purchase price that the buyer retains at closing and releases later, in one or more stages, if an agreed measure stays above an agreed threshold for a defined period. For a clinic pharmacy the measure is usually prescription count, sometimes prescription count from clinic prescribers specifically, measured monthly or quarterly over a period the parties negotiate (twelve to twenty four months after closing is a common choice in our experience, not a standard). If volume holds, the vendor receives the full price. If it falls below the threshold, the holdback is reduced by a formula, or forfeited.
An earnout works in the other direction. The base price reflects the buyer’s cautious view and the vendor earns additional payments if volume or EBITDA exceeds agreed levels. Earnouts suit situations where the vendor believes growth is coming, for example a clinic that is adding physicians.
Both structures need three things to work: a measure that both parties can verify from the pharmacy system, a threshold that reflects normal variation rather than a best month, and a clear statement of what the buyer may and may not change in the operation during the measurement period. A vendor who agrees to a holdback and then watches the buyer cut hours, drop delivery and lose the patients has a legitimate complaint, so the agreement should say what the buyer will maintain.
A vendor transition period is often part of the same package. The vendor pharmacist stays on for a defined period after closing, keeping the relationship with the clinic and the patients in place while the buyer becomes known. In Alberta this can also keep eligible clinical services running while the buyer recruits, but only for services the vendor pharmacist personally provides, is authorized to bill and documents, within the per pharmacist cap. Billing capacity belongs to the individual pharmacist, not the store, and it does not transfer with the sale.
Two examples
The two listings below show how the same feature reads differently depending on the numbers around it. Only publicly released details are given.
A community pharmacy north of Calgary, on the Highway 2 corridor, shares its building with a medical clinic. Revenue was roughly $3.6 million for the year to March 2026 and normalized EBITDA about $919,000, with a national banner in place through January 2030. The questions a buyer asks are the ones above: how many physicians, what share of prescriptions each writes, what lease terms, and who controls the building.
A Surrey community pharmacy in British Columbia is attached to an active medical clinic with multiple practising physicians. Revenue was approximately $1.28 million in 2025 with about 33,000 prescriptions a year, and the lease runs to 2030 with extensions available. Here the likely question is diversification. Several practising physicians can mean that no single retirement moves the business, but head count alone does not prove it: a buyer should still measure each prescriber’s actual share of prescriptions and check whether the physicians depend on one clinic owner’s decisions. A buyer’s attention then shifts to the lease and to BC’s lower public plan dispensing fee. PharmaCare’s maximum is $11.00, while Alberta’s government plan fee rose from $12.15 to $12.35 on 1 October 2026 for supplies under 84 days ($13.50 for 84 days or more). These are public plan maximums; other payers may pay differently.
Same feature, different risk profile, different questions. That is the whole discipline of valuing a clinic pharmacy.
For sellers: how to present a clinic pharmacy
Assemble the prescriber breakdown for three years before you list, and be ready to discuss each physician’s age and plans. Prepare an aggregated, de identified summary of where patients live (for example, the share of active patients by distance band or by postal prefix, with small counts suppressed) to share under the NDA; identifiable patient records transfer only at closing. Provide both leases, or the building title if you own it, and be clear about what you are offering the buyer: a new lease, a lease assignment, or the building itself. Disclose any relationship you have with the clinic entity. If you know a physician is leaving, say so, because the buyer will find out and a disclosed risk is priced while a discovered one can kill the deal.
Then decide in advance how much structure you will accept. A vendor who says at the outset that a reasonable holdback on clinic volume is acceptable, with a transition period, signals confidence in the relationship and can keep buyers who would otherwise walk. In our experience, that is usually more productive than arguing about whose patients they are.
If you own a pharmacy attached to a clinic and want a view on what it is worth, or you are a buyer looking at one, contact us for a confidential conversation.